Anti-Obesity Drugs Market By Drug Class (Orlistat, GLP-1 Receptor Agonists, Phentermine & Topiramate Combination, Bupropion & Naltrexone Combination, Liraglutide, Other Drug Classes), By Mechanism of Action (Appetite Suppressants, Lipase Inhibitors, Thermogenesis Enhancers, Neurotransmitter Modulators), By Route of Administration (Oral, Injectable, Transdermal, Intranasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Direct to Consumer), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Anti-Obesity Drugs Market was valued at USD 3.8 billion in 2023 and will surpass USD 6.1 billion by 2030; growing at a CAGR of 7.1% during 2024 - 2030.

The global anti-obesity drugs market is witnessing rapid growth due to the rising prevalence of obesity and related chronic diseases, along with the increasing demand for pharmacological weight management solutions. Obesity is now recognized as a significant health concern worldwide, which has prompted both private and public sector investments in the development of effective treatments. With an expanding pipeline of novel weight loss drugs, the market is set to evolve, providing a range of therapeutic options that address various obesity-related complications. The market is segmented by drug class, mechanism of action, route of administration, and distribution channel, with each segment catering to different consumer preferences and healthcare needs.

GLP-1 Receptor Agonists Segment Is Fastest Growing Owing to Increasing Effectiveness and Adoption

Among the drug classes, GLP-1 receptor agonists are emerging as the fastest-growing segment in the anti-obesity drugs market. This class of drugs works by mimicking the glucagon-like peptide-1 (GLP-1), a hormone that regulates insulin release and appetite. GLP-1 receptor agonists such as semaglutide have been shown to significantly reduce body weight, leading to their growing adoption in the treatment of obesity. These drugs have gained approval in multiple regions and are increasingly favored due to their dual benefits in managing obesity and Type 2 diabetes, a common co-morbidity in obese individuals. The demand for these drugs is expected to continue rising as healthcare systems prioritize obesity treatment to reduce the risk of associated conditions like cardiovascular diseases and diabetes.

Appetite Suppressants Mechanism of Action Is Largest Due to Popularity and Established Efficacy

The appetite suppressants mechanism of action is the largest segment within the anti-obesity drugs market. Appetite suppressants function by altering the central nervous system to reduce hunger signals, leading to reduced food intake and weight loss. These drugs are among the most prescribed for obesity management due to their direct and relatively rapid effect on appetite. Medications such as phentermine, which have been used for decades, are well-known for their efficacy in promoting short-term weight loss. Appetite suppressants remain the first-line treatment for many patients, especially in regions with high demand for quick results. As such, they continue to dominate the market, driving a significant share of the overall anti-obesity drug sales.

Oral Route of Administration Is Most Common, Offering Convenience and Compliance

Among the various routes of administration, the oral segment holds the largest share in the anti-obesity drugs market. Oral medications are preferred by many patients due to their convenience and ease of use. Drugs such as orlistat and phentermine are available in oral formulations, which simplify adherence to prescribed regimens. The widespread acceptance of oral anti-obesity drugs can be attributed to their cost-effectiveness and the non-invasive nature of the treatment, which eliminates the need for injections or other complex delivery systems. Given their familiarity and established safety profiles, oral drugs remain the primary choice for obesity treatment in both clinical and home settings.

Retail Pharmacies Distribution Channel Is Largest Owing to Accessibility and Convenience

The retail pharmacies segment is the largest in the anti-obesity drugs market in terms of distribution channels. Retail pharmacies provide direct access to consumers, ensuring high availability of weight loss medications in convenient locations. Consumers often prefer to obtain anti-obesity drugs from retail pharmacies due to the immediate availability and ease of access. Moreover, the increasing adoption of over-the-counter weight loss products has boosted this segment, enabling individuals to manage their weight loss journey independently. The ease of purchasing from retail outlets combined with the growing availability of newer anti-obesity drugs in this channel is expected to continue driving the segment's dominance.

North America Is Largest Region Driven by High Obesity Prevalence and Advanced Healthcare Infrastructure

North America remains the largest region for the anti-obesity drugs market. The region’s high obesity rates, advanced healthcare infrastructure, and increased public awareness about obesity-related health risks are key factors fueling market growth. The United States, in particular, has a well-established market for anti-obesity drugs, supported by extensive research into obesity treatments and strong reimbursement systems. The demand for obesity management solutions, including pharmacological treatments, is further amplified by government initiatives aimed at addressing the obesity epidemic. North America’s dominance in this market is expected to persist as new therapies are approved and consumer demand for weight management solutions continues to rise.

Competitive Landscape and Leading Companies

The anti-obesity drugs market is competitive, with several major pharmaceutical companies leading the charge in drug development and commercialization. Key players include Novo Nordisk, Eli Lilly and Company, GlaxoSmithKline, and Pfizer, among others. These companies are focusing on expanding their product portfolios through new drug approvals and strategic partnerships. Novo Nordisk is particularly prominent with its GLP-1 receptor agonist, Wegovy, which has seen substantial market uptake. In addition, Eli Lilly and Bristol-Myers Squibb are actively engaged in research to develop next-generation anti-obesity drugs. The competitive landscape is further evolving as companies focus on addressing unmet medical needs, particularly for patients with obesity-related comorbidities, and on improving drug efficacy and safety profiles to enhance patient compliance and satisfaction. The ongoing innovation and collaboration in the market suggest that the anti-obesity drug segment will continue to see dynamic growth in the coming years.

List of Leading Companies:

• Novo Nordisk
• Eli Lilly and Company
• Bristol-Myers Squibb
• GlaxoSmithKline
• Pfizer Inc.
• Orexigen Therapeutics
• Sanofi S.A.
• AstraZeneca
• Roche
• AbbVie
• Johnson & Johnson
• Amgen Inc.
• Bayer AG
• Mylan N.V.
• Allergan

Recent Developments:

• Novo Nordisk has expanded its GLP-1 receptor agonist Wegovy for obesity treatment across European markets, aiming to address the growing obesity epidemic.
• Eli Lilly submitted a new obesity treatment to the FDA for approval, expanding its portfolio in the anti-obesity market.
• Bristol-Myers Squibb acquired a promising anti-obesity drug developer to strengthen its pipeline of weight-loss medications.
• Pfizer entered into a strategic partnership with a biotech company to co-develop innovative treatments for obesity management.
• Sanofi’s new weight-loss drug received approval from the FDA, marking a significant step forward in their portfolio of obesity therapies.

Report Scope: